Top

Published in:

01-04-2008 | Original Paper

α-Synuclein pathology in the neostriatum in Parkinson’s disease

Authors: Fumiaki Mori, Kunikazu Tanji, Haixin Zhang, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayashi

Published in: Acta Neuropathologica | Issue 4/2008

Abstract

We immunohistochemically examined the neostriatum from 25 patients with symptomatic and presymptomatic Parkinson’s disease (PD) with various degrees of Lewy body pathology, using anti-phosphorylated α-synuclein (αS) antibody. These patients were classified according to the PD staging proposed by Braak et al. (Neurobiol Aging 24:197–211, 2003): stage II (αS pathology confined to the medulla oblongata and pontine tegmentum), stage III (αS pathology confined to the brainstem), stage IV (limbic stage), and stages V and VI (neocortical stage). αS immunohistochemistry revealed neuronal and glial cytoplasmic inclusions and neuritic changes in the neostriatum. αS inclusions were found in the medium-sized neurons (GABAergic neurons that project to the globus pallidus) and large neurons (cholinergic interneurons); the former began to appear at stage III and the latter was noted at stages V and VI. Neuritic changes and glial inclusions also began to appear at stage III. The numbers of neuronal and glial inclusions, and the extent of neuritic changes, correlated with the PD stage (P < 0.001). These findings suggest that intrinsic neostriatal neurons degenerate through αS aggregation during PD progression.

Arai T, Ueda K, Ikeda K, Akiyama H, Haga C, Kondo H, Kuroki N, Niizato K, Iritani S, Tsuchiya K (1999) Argyrophilic glial inclusions in the midbrain of patients with Parkinson’s disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein. Neurosci Lett 259:83–86PubMedCrossRef

Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884PubMed

Bäckman CM, Shan L, Zhang Y, Hoffer BJ, Tomac AC (2007) Alterations in prodynorphin, proenkephalin, and GAD67 mRNA levels in the aged human putamen: correlation with Parkinson’s disease. J Neurosci Res 85:798–804PubMedCrossRef

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404PubMedCrossRef

Braak H, Bohl JR, Müller CM, Rüb U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042–2051PubMedCrossRef

Braak H, Sastre M, Del Tredici K (2007) Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease. Acta Neuropathol 114:231–241PubMedCrossRef

Bugiani O, Perdelli F, Salvarani S, Leonardi A, Mancardi GL (1980) Loss of striatal neurons in Parkinson’s disease: a cytometric study. Eur Neurol 19:339–344PubMedCrossRef

Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205–210PubMedCrossRef

10.

Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ (2002) Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104:7–11PubMedCrossRef

11.

Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55:259–272PubMedCrossRef

12.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164PubMedCrossRef

13.

Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, Hardy J, Dickson DW (2000) Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 99:663–672PubMedCrossRef

14.

Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2001) Widespread occurrence of argyrophilic glial inclusions in Parkinson’s disease. Neuropathol Appl Neurobiol 27:362–372PubMedCrossRef

15.

Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 105:341–350PubMed

16.

Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 112:253–260PubMedCrossRef

17.

Kimura H, McGeer PL, Peng F, McGeer EG (1980) Choline acetyltransferase-containing neurons in rodent brain demonstrated by immunohistochemistry. Science 208:1057–1059PubMedCrossRef

18.

Kosaka K (1978) Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol 42:127–134PubMedCrossRef

19.

Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM (2004) Fibrillization of α-synuclein and tau in familial Parkinson’s disease caused by the A53T α-synuclein mutation. Exp Neurol 187:279–288PubMedCrossRef

20.

Levy R, Herrero MT, Ruberg M, Villares J, Faucheux B, Guridi J, Guillen J, Luquin MR, Javoy-Agid F, Obeso JA et al (1995) Effects of nigrostriatal denervation and l-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson’s disease: an in situ hybridization study of GAD67 mRNA. Eur J Neurosci 7:1199–1209PubMedCrossRef

21.

Lloyd KG, Mohler H, Heitz P, Bartholini G (1975) Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients. J Neurochem 25:789–795PubMedCrossRef

22.

McGeer PL, McGeer EG, Wada JA, Jung E (1971) Effects of globus pallidus lesions and Parkinson’s disease on brain glutamic acid decarboxylase. Brain Res 32:425–431PubMedCrossRef

23.

McNeill TH, Brown SA, Rafols JA, Shoulson I (1988) Atrophy of medium spiny I striatal dendrites in advanced Parkinson’s disease. Brain Res 455:148–152PubMedCrossRef

24.

Nishie M, Mori F, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T, Takahashi H, Wakabayashi K (2004) Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 107:292–298PubMedCrossRef

25.

Parent A, Hazrati LN (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20:91–127PubMedCrossRef

26.

Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMedCrossRef

27.

Piao YS, Wakabayashi K, Hayashi S, Yoshimoto M, Takahashi H (2000) Aggregation of α-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clin Neuropathol 19:163–169PubMed

28.

Rinne JO, Laihinen A, Lonnberg P, Marjamaki P, Rinne UK (1991) A post-mortem study on striatal dopamine receptors in Parkinson’s disease. Brain Res 556:117–122PubMedCrossRef

29.

Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMed

30.

Shoji M, Harigaya Y, Sasaki A, Ueda K, Ishiguro K, Matsubara E, Watanabe M, Ikeda M, Kanai M, Tomidokoro Y, Shizuka M, Amari M, Kosaka K, Nakazato Y, Okamoto K, Hirai S (2000) Accumulation of NACP/α-synuclein in Lewy body disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 68:605–608PubMedCrossRef

31.

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-Synuclein in Lewy bodies. Nature 388:839–840PubMedCrossRef

32.

Takao M, Ghetti B, Yoshida H, Piccardo P, Narain Y, Murrell JR, Vidal R, Glazier BS, Jakes R, Tsutsui M, Spillantini MG, Crowther RA, Goedert M, Koto A (2004) Early-onset dementia with Lewy bodies. Brain Pathol 14:137–147PubMedCrossRef

33.

Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E (1998) Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol 152:367–372PubMed

34.

Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H (1998) Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96:445–452PubMedCrossRef

35.

Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol 99:14–20PubMedCrossRef

36.

Yamaguchi K, Cochran EJ, Murrell JR, Polymeropoulos MH, Shannon KM, Crowther RA, Goedert M, Ghetti B (2005) Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the α-synuclein gene. Acta Neuropathol 110:298–305PubMedCrossRef

37.

Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64:545–547PubMed

38.

Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ (2006) Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 66:1591–1593PubMedCrossRef

Title: α-Synuclein pathology in the neostriatum in Parkinson’s disease
Authors: Fumiaki Mori
Kunikazu Tanji
Haixin Zhang
Akiyoshi Kakita
Hitoshi Takahashi
Koichi Wakabayashi
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 4/2008
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-007-0316-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

α-Synuclein pathology in the neostriatum in Parkinson’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

A not entirely benign procedure: progression of Parkinson’s disease

Kurt Jellinger Prize 2008 for Outstanding Scientific Writing in Neuropathology

Clarifying the pathological progression of Parkinson’s disease

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance

The progression of pathology in longitudinally followed patients with Parkinson’s disease

Curcumin inhibits aggregation of α-synuclein